A study describes an additivity model that can be used to predict the likelihood of success or failure of combination therapies in phase III trials

Certain immunotherapy combinations that are effective in selected solid tumours may not be effective in lung cancer without targetable genetic alterations.

A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors 

Analysis from MARIPOSA-2 and FLAURA2 trials show a potential change of treatment paradigm in both first- and second-line settings

In an early-phase study, the selective inhibitor nanatinostat was well tolerated with evidence of antitumour activity in combination with antiviral therapy

However, lack of OS benefit limits the clinical impact of the findings from the PSMAfore trial 

Clinically meaningful improvements over standard care were observed in both first and second line, as reported in the MARIPOSA and MARIPOSA-2 phase III trials 

Long-term data from monarchE supports dose reduction while NATALEE data reinforces consistency across subgroups

Novel targeted strategies are investigated in uveal melanoma, especially for those who do not respond to the bispecific fusion protein, with some encouraging early-phase data from c-MET/PKC inhibitors

Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed